Literature DB >> 33368853

Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19.

Andrew H Briggs1, Daniel A Goldstein2, Erin Kirwin3,4, Rachel Meacock4, Ankur Pandya5, David J Vanness6, Torbjørn Wisløff7.   

Abstract

Many epidemiological models of the COVID-19 pandemic have focused on preventing deaths. Questions have been raised as to the frailty of those succumbing to the COVID-19 infection. In this paper we employ standard life table methods to illustrate how the potential quality-adjusted life-year (QALY) losses associated with COVID-19 fatalities could be estimated, while adjusting for comorbidities in terms of impact on both mortality and quality of life. Contrary to some suggestions in the media, we find that even relatively elderly patients with high levels of comorbidity can still lose substantial life years and QALYs. The simplicity of the method facilitates straightforward international comparisons as the pandemic evolves. In particular, we compare five different countries and show that differences in the average QALY losses for each COVID-19 fatality is driven mainly by differing age distributions for those dying of the disease.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  COVID-19; QALYs; life tables; quality-adjusted life-years

Year:  2020        PMID: 33368853     DOI: 10.1002/hec.4208

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  18 in total

1.  Count the cost of disability caused by COVID-19.

Authors:  Andrew Briggs; Anna Vassall
Journal:  Nature       Date:  2021-05       Impact factor: 49.962

2.  Predicting mortality in The Irish Longitudinal Study on Ageing (TILDA): development of a four-year index and comparison with international measures.

Authors:  Soraya Matthews; Mark Ward; Anne Nolan; Charles Normand; Rose Anne Kenny; Peter May
Journal:  BMC Geriatr       Date:  2022-06-21       Impact factor: 4.070

3.  The impact of COVID-19 vaccination in prisons in England and Wales: a metapopulation model.

Authors:  Mark Jit; Frank Sandmann; Ciara V McCarthy; Oscar O'Mara; Edwin van Leeuwen
Journal:  BMC Public Health       Date:  2022-05-18       Impact factor: 4.135

4.  Early-death weeks associated with COVID-19: a comparison among France, the UK and the USA.

Authors:  Vu Manh Cuong
Journal:  J Public Health (Oxf)       Date:  2021-12-21       Impact factor: 2.341

5.  A model framework for projecting the prevalence and impact of Long-COVID in the UK.

Authors:  Chris Martin; Michiel Luteijn; William Letton; Josephine Robertson; Stuart McDonald
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

6.  Different approaches to quantify years of life lost from COVID-19.

Authors:  Tamás Ferenci
Journal:  Eur J Epidemiol       Date:  2021-06-10       Impact factor: 8.082

7.  A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine.

Authors:  Erin Kirwin; Ellen Rafferty; Kate Harback; Jeff Round; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2021-06-17       Impact factor: 4.981

8.  Lives saved and lost in the first six month of the US COVID-19 pandemic: A retrospective cost-benefit analysis.

Authors:  Olga Yakusheva; Eline van den Broek-Altenburg; Gayle Brekke; Adam Atherly
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.752

9.  COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.

Authors:  Carl A B Pearson; Fiammetta Bozzani; Simon R Procter; Nicholas G Davies; Maryam Huda; Henning Tarp Jensen; Marcus Keogh-Brown; Muhammad Khalid; Sedona Sweeney; Sergio Torres-Rueda; Rosalind M Eggo; Anna Vassall; Mark Jit
Journal:  PLoS Med       Date:  2021-10-04       Impact factor: 11.069

10.  Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region.

Authors:  Yang Liu; Frank G Sandmann; Rosanna C Barnard; Carl A B Pearson; Roberta Pastore; Richard Pebody; Stefan Flasche; Mark Jit
Journal:  medRxiv       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.